BioNTech (BNTX) is trading higher Friday as investors focus on a fresh procedural win for Pfizer and BioNTech in their COVID-19 patent fight with Moderna. A U.S. Patent Office tribunal decision to cancel two Moderna vaccine patents is being interpreted as a potential weakening of parts of Moderna’s infringement case, easing an overhang that has periodically weighed on sentiment toward Comirnaty-related cash flows and legacy COVID litigation exposure. (tradingview.com)

While BioNTech’s growth narrative has shifted toward oncology and multiple late-stage programs, the stock remains reactive to legal outcomes tied to the COVID franchise because they can influence downside-risk framing (damages, royalties, and settlement leverage). The patent-office cancellation does not end the litigation on its own, but it can reshape leverage and the set of patent claims still in play, which traders often treat as directionally positive for the defendants. (tradingview.com)

The move follows a volatile period for BioNTech after the company’s March 10, 2026 update, when investors refocused on post-COVID revenue dynamics and the timing of oncology catalysts. That backdrop has made incremental news—especially items that remove uncertainty—more impactful on day-to-day trading. (investors.biontech.de)